Medication info
Sitagliptin Metformin Extended-Release Tablet 50/500 mg

Sitagliptin Metformin Extended-Release Tablet 50/500 mg

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.7mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Aliko Pharmaceutical Co., Ltd.
Appearance
Bright blue, bilaterally convex oval extended-release film-coated tablet
Packaging
56 tablets/bottle, 200 tablets/bottle, 28 tablets/bottle
Approval status
Active

MFDS item code 202202017 · Approved 2022.05.13 · Insurance code 656005390

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
In antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine should be taken once daily with a meal, preferably in the evening, and the dose should be gradually increased to reduce gastrointestinal adverse reactions caused by metformin. To maintain its extended-release properties, this medicine must be swallowed whole and must not be split, crushed, ground, or chewed. The 100/1000 mg extended-release tablet of this medicine is taken as 1 tablet once daily. Patients taking the 50/500 mg or 50/1000 mg extended-release tablet of this medicine take 2 tablets together once daily. 1. Patients not currently receiving metformin treatment: For patients with no prior experience of antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be gradually increased up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine. 2. Patients receiving metformin treatment: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial total daily dose of this medicine is sitagliptin 100 mg and the patient's current dose of metformin. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. - Patients taking immediate-release metformin at a current dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this medicine 50/1000 mg extended-release once daily. 3. When adequate glycemic control cannot be achieved with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. The dose should be gradually increased to reduce gastrointestinal adverse reactions caused by metformin. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and <60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and <60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl <45 mL/min or eGFR <45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin.

Ingredients

Manufacturer
Aliko Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is used to improve blood sugar control in patients with type 2 diabetes. It is especially effective when sitagliptin and metformin are taken together, and it supports dietary and exercise regimens. This can lead to more stable management of blood sugar levels. Consistent use can positively impact diabetes management.

How to take

Adult dose

In antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine should be taken once daily with a meal, preferably in the evening, and the dose should be gradually increased to reduce gastrointestinal adverse reactions caused by metformin. To maintain its extended-release properties, this medicine must be swallowed whole and must not be split, crushed, ground, or chewed. The 100/1000 mg extended-release tablet of this medicine is taken as 1 tablet once daily. Patients taking the 50/500 mg or 50/1000 mg extended-release tablet of this medicine take 2 tablets together once daily. 1. Patients not currently receiving metformin treatment: For patients with no prior experience of antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be gradually increased up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine. 2. Patients receiving metformin treatment: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial total daily dose of this medicine is sitagliptin 100 mg and the patient's current dose of metformin. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. - Patients taking immediate-release metformin at a current dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this medicine 50/1000 mg extended-release once daily. 3. When adequate glycemic control cannot be achieved with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. The dose should be gradually increased to reduce gastrointestinal adverse reactions caused by metformin. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and <60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and <60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl <45 mL/min or eGFR <45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin.

Precautions

This medication contains sitagliptin and metformin, which help regulate blood sugar levels. However, severe allergic reactions may occur while taking this medication, so if symptoms such as skin rash, difficulty breathing, or swelling of the face or neck appear, stop taking the medication immediately and consult a physician. Additionally, acute pancreatitis may occur, so if severe abdominal pain, vomiting, or nausea occurs, notify medical personnel immediately. This medication should not be administered to patients with severely decreased kidney function, acute infections, dehydration, severe heart failure, or acute myocardial infarction, and it must be stopped before and after examinations using radiological iodine contrast agents. It is safest for women who are pregnant or of childbearing potential, as well as nursing mothers, to avoid taking this medication. During treatment, symptoms of hypoglycemia may occur, so caution is necessary if meals are skipped or activity levels increase suddenly, and the risk of hypoglycemia may be higher when taken with other blood sugar-lowering agents. Care should also be taken when administering this medication to individuals with impaired liver function, and regular liver and kidney function tests should be conducted. Elderly patients are particularly likely to have decreased kidney function; therefore, dosage adjustments and regular monitoring are necessary. Excessive alcohol consumption may increase the risk of side effects from this medication, so it is advisable to avoid alcohol. If undergoing surgery, this medication should be temporarily discontinued 48 hours before the procedure, and it should be resumed only after the patient’s condition has stabilized and kidney function has been confirmed to be normal. Furthermore, vitamin B12 levels may decrease while taking this medication, so regular blood tests should confirm this, and supplementation should be considered if necessary. Gastrointestinal disturbances, diarrhea, headaches, upper respiratory infections, and other side effects may occur during treatment, and if severe joint pain or skin blisters arise, consult a physician immediately. Lastly, interactions may occur when taking this medication with other drugs, so all currently used medications should be reported to healthcare providers and closely monitored.

Side effects

  • Severe allergic reactions
  • anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory tract infections
  • headache
Show 19 more
  • nausea
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • constipation
  • severe and disabling arthralgia
  • pemphigus-like eruption
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • elevated liver enzymes
  • acute renal failure
  • rash
  • urticaria
  • cutaneous vasculitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it must be stored in a tightly sealed container. Additionally, it is advisable to keep the medication at room temperature, between 1°C and 30°C. Avoid extremely hot or cold places, and store it in a cool place away from direct sunlight.

Appearance and packaging

Appearance

Bright blue, bilaterally convex oval extended-release film-coated tablet

Package unit

56 tablets/bottle, 200 tablets/bottle, 28 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.